China Resources Double-Crane Pharmaceutical Co., Ltd., commonly referred to as Double-Crane, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1999, the company has made significant strides in the development and production of a wide range of pharmaceutical products, including traditional Chinese medicine and modern pharmaceuticals. With a strong operational presence across various regions in China, Double-Crane is dedicated to enhancing healthcare through innovative solutions. The company is renowned for its commitment to quality and research, offering unique formulations that cater to diverse medical needs. Notable achievements include its recognition as a leader in the integration of traditional and modern medicinal practices, solidifying its market position as a trusted provider in the healthcare sector.
How does China Resources Double-Crane Pharmaceutical Co.,Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
China Resources Double-Crane Pharmaceutical Co.,Ltd.'s score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
China Resources Double-Crane Pharmaceutical Co., Ltd., headquartered in CN, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address climate change at this time. As there are no emissions data or reduction initiatives available, it is unclear how China Resources Double-Crane Pharmaceutical aligns with industry standards for carbon management. The absence of emissions reporting may reflect a broader trend within the pharmaceutical sector, where companies are increasingly being urged to disclose their carbon footprints and set ambitious targets to mitigate climate impact. In summary, without available emissions data or climate commitments, China Resources Double-Crane Pharmaceutical Co., Ltd. currently lacks transparency in its environmental performance and initiatives related to carbon emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
China Resources Double-Crane Pharmaceutical Co.,Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
